NanoCellect raises $35M for new development
NanoCellect Biomedical has raised $35 million this year in funding rounds to accelerate the company's commercial growth plans and new product development goals. Read More
Diadem Biotherapeutics wins Amgen's Golden Ticket award
Diadem Biotherapeutics has been awarded the first Amgen Golden Ticket award, winning one year of lab space at BioLabs LA at the Lundquist Institute in West Carson, CA. Read More
Ginkgo Bioworks to go public in SPAC deal worth over $1.6B
Cell programming company Ginkgo Bioworks will go public after it finalizes a $1.6 billion deal with Soaring Eagle Acquisition, a special purpose acquisition company (SPAC). Read More
ThermoGenesis wins NIH grant for cell-processing disposable product
ThermoGenesis has received a $250,000 Small Business Innovation Research phase I grant from the U.S. National Institutes of Health (NIH) to develop and test the company's single-use sterile cell-processing disposable product. Read More
Bio-Techne launches iPSC expansion medium
Bio-Techne has unveiled ExCellerate iPSC Expansion Medium, a new medium to support the expansion and maintenance of induced pluripotent stem cells (iPSCs) for research and translational applications. Read More
Twist inks collaboration deal with Adicet Bio
Twist Bioscience and Adicet Bio will collaborate on the discovery and development of gamma delta T-cell cancer therapies. Read More
New gene therapy platform shows potential against certain muscle diseases
Scientists have engineered a new family of adeno-associated viruses (AAVs) to deliver therapeutic genes to muscle tissue at 100 to 250 times lower doses than previous AAV vectors, potentially reducing the risk of liver damage and other serious side effects, according to a new study published in Cell on September 9. Read More
Agenus launches SaponiQx subsidiary
Agenus is launching a new subsidiary dedicated to novel adjuvant discovery and vaccine design, the company announced. Read More
ONK Therapeutics awarded patents for CISH knockout in NK cells
The U.S. Patent and Trademark Office has granted ONK Therapeutics patents covering the company's cytokine-inducible SH2-containing (CISH) knockout in NK cells, irrespective of the source of the NK cells. Read More
Mammoth raises $195M for CRISPR products
Mammoth Biosciences has raised $195 million in financing that will enable the company to broaden its toolkit of next-generation CRISPR systems. Read More
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter